Flow cytometric analysis of human PBMCs were stimulated 2 days with 10 μg/ml PHA (right panel) or unstimulated (left panel) were stained with SDT Biotin Mouse Anti-Human CD274 Antibody at 5 μl/test followed by Sav-PE. Flow cytometry and data analysis were performed using Agilent NovoCyte Quanteon and FlowJo™ software.
Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | CD274 |
| Location | Cell membrane |
| Accession | Q9NZQ7 |
| Clone Number | 29E.2A3 |
| Antibody Type | Mouse mAb |
| Isotype Control | S0B5556 |
| Application | FCM |
| Reactivity | Hu |
| Positive Sample | PHA stimulated human PBMC |
| Purification | Protein A |
| Concentration | 0.2 mg/ml |
| Conjugation | Biotin |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, 0.09% sodium azide |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 5μl per million cells in 100μl volume | Hu |
Background
CD274, also known as PD-L1 (Programmed Death-Ligand 1), is a ~33 kDa type I transmembrane glycoprotein of the immunoglobulin superfamily that functions as the key ligand for the inhibitory receptor PD-1 on T cells; upon IFN-γ–driven up-regulation on dendritic cells, macrophages, normal epithelia and many tumors, its engagement of PD-1 delivers a “stop” signal that blocks T-cell receptor signaling, suppressing proliferation, cytokine production and cytotoxic activity, thereby maintaining peripheral tolerance and preventing autoimmunity, but is exploited by cancers to evade immune destruction, making the PD-1/PD-L1 axis a central target for modern checkpoint-inhibitor immunotherapies.
Picture
Picture
FC
